Concourse Financial Group Securities, Inc. Trevi Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$2.58 - $3.51 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.44 - $3.36 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.3 - $3.7 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.06 - $2.05 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$2.11 - $2.47 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$2.11 - $2.47 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.8 - $3.44 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.69 - $2.97 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.61 - $2.42 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.54 - $4.28 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.8 - $3.39 $0 - $0
Q1 2022 May 09, 2022	BUY	$0.46 - $2.48 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$0.68 - $1.5 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$1.29 - $2.18 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$2.0 - $2.76 $0 - $0
Q1 2021 May 13, 2021	BUY	$2.36 - $3.55 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$2.42 - $3.99 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$3.5 - $7.62 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$2.51 - $6.87 $0 - $0
Q1 2020 May 13, 2020	BUY	$1.71 - $5.87 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$2.78 - $4.7 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$4.2 - $7.79 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$7.5 - $10.12 $0 - $0

Others Institutions Holding TRVI

# of Institutions

Shares Held

57.1M

Call Options Held

136K

Put Options Held

5.4K

Nea Management Company, LLC Timonium, MD

11.4M
Shares

$31.5 Million
2.9% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

7.38M
Shares

$20.4 Million
1.33% of portfolio
Rubric Capital Management LP New York, NY

5.03M
Shares

$13.9 Million
0.47% of portfolio
Viking Global Investors LP

4.4M
Shares

$12.2 Million
0.06% of portfolio
Vr Adviser, LLC New York, NY

3.42M
Shares

$9.48 Million
1.18% of portfolio

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $162M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account